ZEVRA THERAPEUTICS INC
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | Other Information |
|---|
(a) Disclosure in lieu of reporting on a Current Report on Form8-K.
None.
(b) Material changes to the procedures by which security holders* may*recommend nominees to the board of directors.
None.
(c) Insider Trading Arrangements and Policies.
On* October 15, 2024,Timothy J. Sangiovanni, Senior Vice President, Finance and Corporate Controller, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 3,000 shares of the Company’s common stock until* April 15, 2025.*
On* October 15, 2024,Sven Guenther, Ph.D., Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 8,000 shares of the Company’s common stock until* April 15, 2025.*
On* October 15, 2024,Joshua Schafer, Chief Commercial Officer & Executive Vice President, Business Development, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 10,500 shares of the Company’s common stock until* April 15, 2025.*
On* October 15, 2024,Christal M.M. Mickle, Chief Development Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 6,300 shares of the Company’s common stock until* April 15, 2025.*
On* October 15, 2024,R. LaDuane Clifton, Chief Financial Officer and Treasurer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 11,000 shares of the Company’s common stock until* April 15, 2025.*
On* October 15, 2024,Neil F. McFarlane, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule10b5*-1(c) for the sale of up to 91,817 shares of the Company’s common stock until* April 15, 2025.*
Other than as disclosed above, during thethree months ended* September**30,* 2024, no director or officer of the Company adopted or terminated a “Rule10b5-1 trading arrangement” or “non-Rule10b5-1 trading arrangement,” as each term is defined in Item408(a) of Regulation S-K.
42
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.